Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519. by Mol-Alma, Harma et al.
 
 
 University of Groningen
Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically
Important Differences in the Assessment of New Medicines for Chronic Obstructive
Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519.





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Mol-Alma, H., Jong, de, C., Kocks, J. W. H., & Molen, van der, T. (2020). Commentary: “Healthcare
Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment
of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in
Pharmacology 2020; 10: 1519. Frontiers in Pharmacology, 11, [827]. https://doi.org/doi:
10.3389/fphar.2020.00827
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020







University of Salerno, Italy
Antonio Molino,





This article was submitted to
Respiratory Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 29 March 2020
Accepted: 19 May 2020
Published: 02 June 2020
Citation:
Alma H, de Jong C, Kocks J and van
der Molen T (2020) Commentary:
“Healthcare Professionals’ Preferred
Efficacy Endpoints and Minimal
Clinically Important Differences in the
Assessment of New Medicines for
Chronic Obstructive Pulmonary






published: 02 June 2020
doi: 10.3389/fphar.2020.00827Commentary: “Healthcare
Professionals’ Preferred Efficacy
Endpoints and Minimal Clinically
Important Differences in the
Assessment of New Medicines for
Chronic Obstructive Pulmonary
Disease” by Dankers M et al. in
Frontiers in Pharmacology 2020;
10: 1519
Harma Alma1,2*, Corina de Jong1,2, Janwillem Kocks2,3,4 and Thys van der Molen1,2
1 Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen,
Groningen, Netherlands, 2 GRIAC Research Institute, University of Groningen, University Medical Center Groningen,
Groningen, Netherlands, 3 General Practitioners Research Institute, Groningen, Netherlands, 4 Observational and Pragmatic
Research Institute, Singapore, Singapore
Keywords: health status, COPD, (MCID) minimal clinically important difference, St. George’s Respiratory
Questionnaire, patient-reported outcomesA Commentary on
Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important
Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease
by Dankers M, Nelissen-Vrancken MHJMG, Surminski SMK, Lambooij AC, Schermer TR and van
Dijk L. Front Pharmacol (2020) 10:1519. doi: 10.3389/fphar.2019.01519
INTRODUCTION
Pharmacological clinical trials require obligatory endpoints in evaluating the clinical relevance of
their outcomes (Jones, 2001; US Department of Health and Human Services FDA Center for Drug
Evaluation and Research, 2006). The minimal clinically important difference (MCID) is an
important parameter that represents the threshold of an outcome measure at which the observedin.org June 2020 | Volume 11 | Article 8271
Alma et al. Commentary: Healthcare Professionals’ Preferred Endpointschange can be considered clinically relevant for the patient,
hence justifying the therapy (Jaeschke et al., 1989). Frequently
applied endpoints in clinical trials for patients with chronic
obstructive pulmonary disease (COPD) include spirometry
with forced expiratory volume in one second (FEV1),
exacerbations, and health status (US Department of Health
and Human Services FDA Center for Drug Evaluation and
Research, 2006; Jones et al., 2012; Cazzola et al., 2015).
The most frequently selected health status instrument in
scientific research is the St. George’s Respiratory Questionnaire
(SGRQ) with a proclaimed MCID of four units on a total scale
from 0 to 100 (Jones et al., 1991; US Department of Health and
Human Services FDA Center for Drug Evaluation and
Research, 2006; Jones et al., 2012). Higher scores represent
worse health status. MCIDs can be determined using anchor-,
distribution-, or opinion-based methods (Copay et al., 2007). It
is with great interest that Dankers et al. have investigated
healthcare professionals’ opinion on among others the MCID
threshold of the SGRQ. To our knowledge, this is the first study
to investigate these expert-ratings on the MCID of the SGRQ.
The authors’ conclusion was that healthcare professionals
prefer a higher cutoff value for clinical relevance of 11 on the
SGRQ instead of the currently used MCID of four by
registration authorities.REDEFINING THE MCID OF THE SGRQ
We agree with Dankers et al. that the MCID of the SGRQ should
in fact be higher than four points, and that current clinical trials
hence may have overestimated the interpretation of treatment
effects. In general, MCIDs of instruments are approximately 7–
10% of the maximum scale score (Copay et al., 2007). This would
represent a change of 7–10 points on the SGRQ. In a published
systematic review in the European Respiratory Journal, Alma
et al. (2018b) reviewed the available content on the MCID of
COPD health status tools including the SGRQ (Alma et al.,
2018b). A meta-analysis by means of triangulation procedures
was performed and resulted in weighted MCID cutoff values of
−7.43 (4 studies, range −10.19 to −2.40) for the SGRQ; −2.54 (6
studies, range −3.80 to −1.00) for the COPD Assessment Test
(CAT); and −0.43 (5 studies, range −0.62 to −0.21) for the
Clinical COPD Questionnaire (CCQ).
Moreover, multiple publications emerged over the past few
years on the MCID of the SGRQ, proclaiming that this threshold
should in fact be higher than four units (Welling et al., 2015;
Alma et al., 2016; Alma et al., 2018a; Alma H.J. et al., 2019; Alma
H. et al., 2019). Figure 1 summarizes the evidence from these
publications. The majority of estimates is in the range of five to
nine points depending on the study setting as well as the
direction of the measured change (improvement versusAbbreviations: 95%CI, 95% confidence interval; BLVR, bronchoscopic lung
volume reduction; MCID, minimal clinically important difference; PR,
pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St. George’s
Respiratory Questionnaire.
Frontiers in Pharmacology | www.frontiersin.org 2deterioration). Only MCID estimates from routine clinical
practice come somewhat close (range three to six points) to the
proclaimed MCID of four units (Jones, 2005).
We would like to highlight that experts’ opinions on the
MCID of the SGRQ are of interest as they convey a message of
clinical judgment; however there is clear evidence that ratings by
physicians and patients on quality of life and MCIDs are not in
line (Janse et al., 2004). What relevance does an expert-based
MCID of 11 units have, if it does not match with the experienced
change by the patient with COPD? Especially since the SGRQ is
defined as a patient-reported outcome (PRO). It is also
remarkable that experts in the Netherlands were asked about a
questionnaire like the SGRQ, without being very familiar with it.
Ratings were based upon a short description of the questionnaire
and its total scoring range. On what was the respondent’s
judgment based? Was it just a gut-feeling or was there actually
rationale for? Since it is known that Dutch healthcare
professionals have more experience with the CCQ (Van der
Molen et al., 2003; Snoeck-Stroband et al., 2015), one would
think ratings for this clinically applied tool, would be more
reliable than for an instrument that is infrequently used. It would
make more sense to formulate a threshold for something
complicated as an MCID, once the professional has knowledge
about its content and clinical application.
It is also interesting to have a closer look at the number of
responders in this analysis, since this was less than 3% of the group
of invited professionals (227 replied out of 7,731 invitations). Is
this representative and was this in fact the group of professionals
most frequently working with patients with COPD and the SGRQ?
Especially since approximately half of this group was a pharmacist,
rather than a physician or practice nurse. Although pharmacists
play a key role in the support of patients with COPD, they do not
work directly with health status instruments in their day-to-day
practice. This inexperience may also be reflected in the large
variation of responses by the healthcare professionals, because
the standard deviation was 10.1 out of the rated overall MCID of
the SGRQ of 11 units.
Last, but not least it is unknown if the professionals reviewed
thresholds at the individual level or at the group level (Beaton
et al., 2001; Kocks et al., 2010). Physicians and healthcare
professionals meet the individual patient in clinical practice,
possibly requiring more change after intervention. In scientific
research, conclusions are drawn based on reaching the MCID
threshold at the group level. Extreme high and low change
scores are usually integrated in the regression to the
mean phenomenon.DISCUSSION
Dankers et al. have an important share in continuing the
discussion on the MCID of the SGRQ. Experts’ opinions on
the threshold of the SGRQ could be valuable, yet should not be
leading. It is very remarkable that despite new studies on the
MCID of the SGRQ, the threshold of four points (Jones, 2005)—
based upon unclear methodology—is still applied in scientific
research. If we continue doing so, trial outcomes could beJune 2020 | Volume 11 | Article 827
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be offered to patients without a valid basis. Possibly with some
good individual responses, but at the group level they may not
meet sufficiently clinically relevant improvements. The newer
health status instruments (like the CCQ and CAT) have shown
better effect sizes and responsiveness, and their MCID is more
rigorously determined. Integrating these measures in future
studies may lead to better assessment of treatment response
than continuing using the SGRQ.Frontiers in Pharmacology | www.frontiersin.org 3AUTHOR CONTRIBUTIONS
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